Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 113Colonic Neoplasms 30Neoplasm Metastasis 28Rectal Neoplasms 27Neoplasms 27Carcinoma, Non-Small-Cell Lung 14Esophageal Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Pancreatic Neoplasms 9Head and Neck Neoplasms 9Lung Neoplasms 8Cholangiocarcinoma 7Carcinoma, Squamous Cell 6Breast Neoplasms 6Colorectal Cancer Metastatic 5Carcinoma 5Triple Negative Breast Neoplasms 4Recurrence 4Prostatic Neoplasms 4Ovarian Neoplasms 4Inflammatory Breast Neoplasms 3Gastrointestinal Neoplasms 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Solid Tumors 2Kidney Neoplasms 2Glioma 2Fallopian Tube Neoplasms 2

Interventions

Panitumumab 1Gemcitabine 1Cystectomy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cone Dystrophy 3 × Panitumumab × Clear all
NCT01916109 2016-02-12

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
4 enrolled 6 charts
Genitourinary

Cone Dystrophy 3, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡